EP0815211A1 - Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung - Google Patents
Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlungInfo
- Publication number
- EP0815211A1 EP0815211A1 EP96907436A EP96907436A EP0815211A1 EP 0815211 A1 EP0815211 A1 EP 0815211A1 EP 96907436 A EP96907436 A EP 96907436A EP 96907436 A EP96907436 A EP 96907436A EP 0815211 A1 EP0815211 A1 EP 0815211A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- collagenase
- cells
- gly
- pro
- enzymes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 90
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 90
- 206010052428 Wound Diseases 0.000 title claims abstract description 13
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 13
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 239000012634 fragment Substances 0.000 claims abstract description 12
- 241000193159 Hathewaya histolytica Species 0.000 claims abstract description 8
- 102000029816 Collagenase Human genes 0.000 claims description 106
- 108060005980 Collagenase Proteins 0.000 claims description 106
- 229960002424 collagenase Drugs 0.000 claims description 97
- 229940088598 enzyme Drugs 0.000 claims description 86
- 238000002955 isolation Methods 0.000 claims description 53
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 34
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 20
- 239000000758 substrate Substances 0.000 claims description 16
- 108090001092 clostripain Proteins 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 11
- 102000016942 Elastin Human genes 0.000 claims description 11
- 108010014258 Elastin Proteins 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 11
- 229920002549 elastin Polymers 0.000 claims description 11
- 238000001962 electrophoresis Methods 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 8
- 238000001502 gel electrophoresis Methods 0.000 claims description 7
- YMMPZCZOLKBHAP-IHPCNDPISA-N (2s)-2-[[(2s)-1-[2-[[2-[[(2s)-1-[2-(phenylmethoxycarbonylamino)acetyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)[C@H]1N(C(=O)CNC(=O)OCC=2C=CC=CC=2)CCC1 YMMPZCZOLKBHAP-IHPCNDPISA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 4
- 108010027805 Azocoll Proteins 0.000 claims description 3
- ZLFQNOJSYZSINX-PVJKAEHXSA-N (2s)-2-[[(2s)-1-[2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]propanoic acid Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C(=O)\C=C\C1=CC=CO1 ZLFQNOJSYZSINX-PVJKAEHXSA-N 0.000 claims description 2
- 108010089930 2-furanacryloyl-leucyl-glycyl-prolyl-alanine Proteins 0.000 claims description 2
- 101710097834 Thiol protease Proteins 0.000 claims description 2
- 230000007691 collagen metabolic process Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 77
- 210000003494 hepatocyte Anatomy 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 34
- 239000000872 buffer Substances 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 25
- 210000004185 liver Anatomy 0.000 description 22
- 238000000034 method Methods 0.000 description 17
- 210000000496 pancreas Anatomy 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 210000004153 islets of langerhan Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000002919 epithelial cell Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 6
- 239000001639 calcium acetate Substances 0.000 description 6
- 235000011092 calcium acetate Nutrition 0.000 description 6
- 229960005147 calcium acetate Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000004365 Protease Substances 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 229940079919 digestives enzyme preparation Drugs 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 235000021028 berry Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 210000003954 umbilical cord Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000145 Bacillolysin Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000035092 Neutral proteases Human genes 0.000 description 3
- 108091005507 Neutral proteases Proteins 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 210000004923 pancreatic tissue Anatomy 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000006920 protein precipitation Effects 0.000 description 3
- 238000011403 purification operation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 230000003366 colagenolytic effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 210000003890 endocrine cell Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WRMRXPASUROZGT-UHFFFAOYSA-N monoethylglycinexylidide Chemical compound CCNCC(=O)NC1=C(C)C=CC=C1C WRMRXPASUROZGT-UHFFFAOYSA-N 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- 230000003246 elastolytic effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- YQDHCCVUYCIGSW-LBPRGKRZSA-N ethyl (2s)-2-benzamido-5-(diaminomethylideneamino)pentanoate Chemical compound NC(=N)NCCC[C@@H](C(=O)OCC)NC(=O)C1=CC=CC=C1 YQDHCCVUYCIGSW-LBPRGKRZSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003547 hepatic macrophage Anatomy 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6448—Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19509584 | 1995-03-16 | ||
| DE19509584 | 1995-03-16 | ||
| DE19532906A DE19532906A1 (de) | 1995-03-16 | 1995-09-07 | Neue, definierte Enzymmischungen zur Zellgewinnung und für die Wundbehandlung |
| DE19532906 | 1995-09-07 | ||
| PCT/EP1996/001044 WO1996028543A1 (de) | 1995-03-16 | 1996-03-12 | Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0815211A1 true EP0815211A1 (de) | 1998-01-07 |
Family
ID=26013440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP96907436A Withdrawn EP0815211A1 (de) | 1995-03-16 | 1996-03-12 | Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6146626A (no) |
| EP (1) | EP0815211A1 (no) |
| JP (1) | JPH11501517A (no) |
| AU (1) | AU702514B2 (no) |
| BR (1) | BR9607143A (no) |
| CA (1) | CA2213723A1 (no) |
| CZ (1) | CZ280397A3 (no) |
| EA (1) | EA000583B1 (no) |
| HU (1) | HUP9901188A2 (no) |
| IL (1) | IL117479A (no) |
| NO (1) | NO974260L (no) |
| PL (1) | PL322271A1 (no) |
| WO (1) | WO1996028543A1 (no) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5718897A (en) * | 1995-06-07 | 1998-02-17 | Trustees Of Tufts College | Enhancing keratinocyte migration and proliferation |
| US5830741A (en) * | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
| WO2003011333A1 (en) * | 2001-07-27 | 2003-02-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
| US7364565B2 (en) | 2001-07-27 | 2008-04-29 | Ramot At Tel Aviv University Ltd. | Controlled enzymatic removal and retrieval of cells |
| US7811560B2 (en) * | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| US8323642B2 (en) * | 2006-12-13 | 2012-12-04 | Depuy Mitek, Inc. | Tissue fusion method using collagenase for repair of soft tissue |
| US20100159564A1 (en) * | 2007-11-30 | 2010-06-24 | Dwulet Francis E | Protease resistant recombinant bacterial collagenases |
| MX2012006661A (es) | 2009-12-08 | 2012-11-12 | Healthpoint Ltd | Composiciones enzimaticas de desbridamiento de heridas con actividad enzimatica mejorada. |
| HUE057423T2 (hu) | 2012-01-12 | 2022-05-28 | Endo Global Ventures | Clostridium histolyticum enzim |
| CN115969318A (zh) | 2017-03-01 | 2023-04-18 | 恩多风投有限公司 | 用于评估和治疗橘皮组织的装置和方法 |
| AU2018244426A1 (en) | 2017-03-28 | 2019-10-17 | Endo Ventures Limited | Improved method of producing collagenase |
| CN109694845A (zh) * | 2018-12-25 | 2019-04-30 | 中国医学科学院北京协和医院 | 用于分离单细胞的试剂盒及其应用 |
| WO2023228873A1 (ja) * | 2022-05-24 | 2023-11-30 | 国立研究開発法人国立成育医療研究センター | 肝細胞の製造方法、肝細胞の接着性改善剤、および肝細胞 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0673456B2 (ja) * | 1986-04-26 | 1994-09-21 | 三共株式会社 | ヒト・膵臓エラスタ−ゼ▲ｉ▼ |
| US5162205A (en) * | 1986-04-26 | 1992-11-10 | Sankyo Company, Limited | Human pancreatic elastase I |
| AU4644793A (en) * | 1992-06-22 | 1994-01-24 | Trigen, Inc. | Molecular cloning of the genes reponsible for collagenase production from clostridium histolyticum |
| WO1996000283A1 (en) * | 1994-06-24 | 1996-01-04 | Boehringer Mannheim Corporation | A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum |
-
1996
- 1996-03-12 BR BR9607143A patent/BR9607143A/pt not_active Application Discontinuation
- 1996-03-12 CZ CZ972803A patent/CZ280397A3/cs unknown
- 1996-03-12 PL PL96322271A patent/PL322271A1/xx unknown
- 1996-03-12 EP EP96907436A patent/EP0815211A1/de not_active Withdrawn
- 1996-03-12 US US08/913,396 patent/US6146626A/en not_active Expired - Fee Related
- 1996-03-12 CA CA002213723A patent/CA2213723A1/en not_active Abandoned
- 1996-03-12 EA EA199700241A patent/EA000583B1/ru not_active IP Right Cessation
- 1996-03-12 JP JP8527270A patent/JPH11501517A/ja active Pending
- 1996-03-12 HU HU9901188A patent/HUP9901188A2/hu unknown
- 1996-03-12 WO PCT/EP1996/001044 patent/WO1996028543A1/de not_active Application Discontinuation
- 1996-03-12 AU AU51066/96A patent/AU702514B2/en not_active Ceased
- 1996-03-14 IL IL11747996A patent/IL117479A/xx active IP Right Grant
-
1997
- 1997-09-15 NO NO974260A patent/NO974260L/no not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9628543A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CZ280397A3 (cs) | 1998-04-15 |
| HUP9901188A2 (hu) | 1999-08-30 |
| IL117479A0 (en) | 1996-07-23 |
| JPH11501517A (ja) | 1999-02-09 |
| EA000583B1 (ru) | 1999-12-29 |
| WO1996028543A1 (de) | 1996-09-19 |
| EA199700241A1 (ru) | 1998-02-26 |
| IL117479A (en) | 1999-12-22 |
| PL322271A1 (en) | 1998-01-19 |
| CA2213723A1 (en) | 1996-09-19 |
| US6146626A (en) | 2000-11-14 |
| BR9607143A (pt) | 1997-11-25 |
| AU702514B2 (en) | 1999-02-25 |
| NO974260D0 (no) | 1997-09-15 |
| AU5106696A (en) | 1996-10-02 |
| NO974260L (no) | 1997-11-14 |
| MX9706725A (es) | 1997-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69735308T2 (de) | Enzymzusammensetzung für die freisetzung von zellen aus geweben. | |
| DE69823361T2 (de) | Herstellung von kollagen | |
| DE60115613T2 (de) | Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien | |
| DE2734821C3 (de) | Blutgerinnungsfördernde Präparation und Verfahren zu ihrer Herstellung | |
| EP0815211A1 (de) | Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung | |
| US20030203008A1 (en) | Preparation of collagen | |
| DE68918922T3 (de) | Biologische Unterlage für Zellkulturen, bestehend aus durch Thrombin koagulierte Plasmaproteine, ihre Verwendung für die Keratinozytenkultur, deren Rückgewinnung und Transport für therapeutische Verwendungszwecke. | |
| EP0209061A2 (de) | Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel | |
| DE69333239T2 (de) | Reinigung von plasmafraktion | |
| WO1996034093A1 (en) | Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells | |
| DE2619667A1 (de) | Pharmazeutisches mittel | |
| DE3617752A1 (de) | Gewebe-plasminogenaktivator, diesen enthaltende pharmazeutische formulierungen, ihre herstellung und ihre verwendung in der human- und veterinaermedizin | |
| DE3230151A1 (de) | Neues polypeptid mit wirkung auf das immunsystem, verfahren zu seiner isolierung und reinigung, seine verwendung, dieses enthaltende mittel sowie seine spaltprodukte, deren verwendung und diese enthaltende mittel | |
| DE2734427A1 (de) | Verfahren zur gewinnung von thrombinartigen enzymen aus schlangengiften | |
| EP1056839A1 (de) | Pharmazeutische formulierung enthaltend ein hyaluronsäure-spaltendes enzym mikrobieller herkunft | |
| DE19532906A1 (de) | Neue, definierte Enzymmischungen zur Zellgewinnung und für die Wundbehandlung | |
| DE3306944A1 (de) | Fibrinolytisch aktives mittel und verfahren zu seiner herstellung | |
| JPWO2002102845A1 (ja) | 絹フィブロイン由来機能性ポリペプチドの製造法及びその利用 | |
| AT392003B (de) | Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat | |
| WO1998001108A1 (de) | Definierte enzymmischungen für kosmetische zwecke | |
| DE19716098A1 (de) | Fibroblasten mit einem Fremdgen enthaltende Zusammensetzung zur Behandlung von Wunden | |
| DE4002166A1 (de) | Verfahren zur herstellung einer suspension zur rekonstruktion von zellmembranen | |
| DE69634090T2 (de) | Verfahren zur verhinderung der aktivität des chymopapain- und ppainenzyms mit tierischen polysacchariden | |
| DE2106706B2 (de) | Verfahren zur herstellung von pankreatin als trockenes pulver mit hoher proteolytischer, amylolytischer und lipolytischer aktivitaet | |
| WO2007143978A2 (de) | Verfahren zur induktion der insulinsynthese in chorionzellen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19970822 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB IT LI NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20000623 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20020522 |